EFFECT OF HESPERIDIN IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN RATS- CRITICAL ROLE OF NRF-2, TNF-Α, AND IL-1Β

Author(s)

Kandhare AD, Mukherjee A, Bodhankar SL
Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India

OBJECTIVES:: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive multifactorial disease with limited successful treatment. Hesperidin possesses potent anti-inflammatory and anti-oxidant property. Hence, the objective of present investigation was to evaluate the effect of hesperidin against bleomycin (BLM) induced pulmonary fibrosis by assessing various behavioral, biochemical, molecular and ultrastructural changes in the laboratory rats. METHODS:: IPF was induced in male Sprague-Dawley rats by single intratracheal BLM (6 IU/kg) injection followed by hesperidin (25, 50 and 100 mg/kg, p.o.) or Methylprednisolone (10 mg/kg, p.o.) treatment for 28 days. Sham control rats received saline instead of BLM. The lung function test, biochemical, histopathological and molecular changes were analyzed in lung and bronchoalveolar lavage fluid (BALF). RESULTS:: Treatment with hesperidin significantly restored (p < 0.05) the BLM-induced alteration in body weight, lung index, lung function test, and hematology. The altered total and differential cell count in BALF and blood was significantly restored (p < 0.05) by hesperidin treatment. The decreased peripheral blood oxygen content after BLM instillation was significantly increased (p < 0.05) by hesperidin treatment. Hesperidin significantly enhanced (p < 0.05) the BALF and lung antioxidant status, through modulating the SOD, GSH, MDA, NO level and Nrf2 mRNA expression. The altered mRNA expression of lung inflammatory markers (TNF-α and IL-1β) were significantly restored (p < 0.05) by hesperidin treatment. BLM-induced histological inflammatory and fibrotic insult in the lung which was reduced by hesperidin treatment. CONCLUSIONS:: Hesperidin has potential anti-fibrotic efficacy through induction of Nrf2 which in turn modulated anti-inflammatory molecules to reduce pathogenesis of BLM-induced pulmonary fibrosis.

Conference/Value in Health Info

2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PRS1

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Neurological Disorders, Respiratory-Related Disorders, Systemic Disorders/Conditions

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×